Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Hoffmann-La Roche
Genentech, Inc.
Hoffmann-La Roche